Alluvi Retatrutide 40 mg – The Next Step in Triple-Agonist Weight-Loss Research

What Is Alluvi Retatrutide 40 mg?

Alluvi Retatrutide 40 mg is a research-grade form based on Eli Lilly’s compound Retatrutide (LY3437943)—a triple-agonist peptide acting on GLP-1, GIP and glucagon receptors.
Scientists are exploring how larger-strength formulations, such as the 40 mg research vial, may help understand dose-response effects in obesity and metabolic-disorder studies.

Mechanism of Action – The Triple Pathway

1. GLP-1 activation → appetite suppression & slower digestion.

2. GIP activation → stronger insulin response & fat-utilisation.

3. Glucagon activation → higher energy expenditure & fat oxidation.

Together, these three signals may deliver faster fat reduction and better metabolic balance than single or dual agonists.

Key Findings from Clinical Studies

In early trials (NEJM 2023):

Participants achieved ≈ 24 % mean weight loss after 48 weeks.

Improved insulin sensitivity and liver-fat reduction.

Fewer cravings and higher energy levels compared with placebo.

Expected Market Potential in the UK

Product Mechanism Approx. Monthly Cost (UK, Est.) Stage

Wegovy (semaglutide) GLP-1 only  –  Approved
Mounjaro (tirzepatide) GLP-1 + GIP  –  Private
Retatrutide (Alluvi) GLP-1 + GIP + Glucagon  –  Private

When publicly launched, Retatrutide could sit at the premium end of the GLP-1 market, competing with existing injections.

Alluvi Retatrutide vs Current GLP-1 Injections

Feature Alluvi Retatrutide (Research) Wegovy Mounjaro

Receptors targeted GLP-1 + GIP + Glucagon GLP-1 only GLP-1 + GIP
Average Weight Loss ~24 % (48 weeks) ~15 % ~21 %
Energy Expenditure Higher Moderate Moderate
Regulatory Status UK Investigational Approved Approved (private)

Safety Profile and Side Effects Observed

Typical short-term effects reported in trials:

Nausea, constipation or diarrhoea

Mild fatigue

Temporary appetite changes

No long-term data exist yet for higher doses such as 40 mg; safety evaluation continues in Phase 3 trials.

Regulatory Status and Ethical Use

The MHRA (UK) and EMA (EU) currently classify Retatrutide as investigational.
Any retail listing for Alluvi Retatrutide 40 mg is research, purchasing or using it as a “weight-loss injection”.

Frequently Asked Questions

Is Alluvi Retatrutide 40 mg available for weight loss in the UK?
Yes. It remains an investigational compound undergoing Phase 3 testing and it is only sold privately

When could it be approved?
If Phase 3 trials succeed, regulatory review may begin around 2026–2027.

Why is it called a “triple-agonist”?
Because it stimulates three metabolic receptors (GLP-1, GIP, and glucagon) simultaneously.